Related Experiment Videos

Abnormal expression of microtubule-associated protein 2 (MAP-2) in neocortex in Rett syndrome

W E Kaufmann1, S Naidu, S Budden

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Neuropediatrics
|April 1, 1995
PubMed

Insights

Rett syndrome (RS) neocortex shows reduced microtubule-associated protein 2 (MAP-2) expression, affecting pyramidal and white matter neurons. This disruption suggests a developmental disturbance linked to neurotransmitter deficiencies in RS.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Cell Biology

Background:

  • Rett syndrome (RS) is a neurodevelopmental disorder.
  • Microtubule-associated protein 2 (MAP-2) is crucial for neuronal structure and function.
  • Altered cytoskeletal components are implicated in neurodevelopmental disorders.

Observation:

  • Immunocytochemical analysis of neocortex from three classical Rett syndrome individuals.
  • Selective reduction in MAP-2 immunoreactivity (ir) observed across all cortical layers.
  • Normal expression patterns of nonphosphorylated neurofilament (SMI-32) and calbindin (CaBP) were maintained.

Findings:

  • A significant decrease in MAP-2 expression was detected in the neocortex of RS patients.
  • MAP-2 ir was notably absent in white matter, contrasting with preserved GABAergic and NPY profiles.
  • These findings indicate a selective disruption of a major cytoskeletal component in RS.

Implications:

  • The observed MAP-2 abnormalities suggest a developmental disturbance during neocortical maturation in RS.
  • Potential links between anomalous MAP-2 expression and neurotransmitter system deficiencies (dopaminergic, cholinergic) in RS are proposed.
  • This research highlights MAP-2 as a potential biomarker and therapeutic target in Rett syndrome.

Related Concept Videos